ImmuCell (ICCC) vs Neumora Therapeutics (NMRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ImmuCell (ICCC) has outperformed Neumora Therapeutics (NMRA) over the past year, gaining 48.0% versus a loss of 75.3%. Neumora Therapeutics is the larger company by market cap ($90.2 million vs $88.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ICCC | NMRA |
|---|---|---|
| Share price | $9.75 | $0.4798 |
| Market cap | $88.55M | $90.15M |
| 1-day change | +0.62% | +2.46% |
| YTD return | +58.54% | -73.20% |
| 1-year return | +47.95% | -75.27% |
| 5-year return | +5.06% | — |
| P/E ratio (TTM) | 139.29 | — |
| EPS (TTM) | $0.07 | $-1.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.10 | $3.65 |
| 52-week low | $4.52 | $0.45 |
| Distance from 52-week high | -19.42% | -86.85% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +1179.70% |
| Average volume | 22.20K | 1.19M |
| Shares outstanding | 9.08M | 187.90M |
| Employees | 73 | 63 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ICCC has outperformed NMRA by 123.2 percentage points over the past year.
About ImmuCell
ICCC stock →ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis.
Healthcare · Biotechnology · 73 employees
About Neumora Therapeutics
NMRA stock →Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Healthcare · Biotechnology · 63 employees
ICCC vs NMRA FAQ
Which is bigger, ImmuCell or Neumora Therapeutics?
Neumora Therapeutics (NMRA) is larger, with a market capitalization of $90.15M compared with $88.55M for ImmuCell (ICCC).
Which stock has performed better over the past year, ICCC or NMRA?
ICCC returned +47.95% over the past 12 months, compared with -75.27% for NMRA (price return, excluding dividends). Past performance does not predict future results.
Are ImmuCell and Neumora Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.